Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib

Creative Commons License

Dogan I., Khanmammadov N., Paksoy N., Ferhatoglu F., Aydın E., Vatansever S., ...Daha Fazla

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.37, ss.413-418, 2022 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5505/tjo.2022.3608
  • Dergi Adı: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE
  • Sayfa Sayıları: ss.413-418
  • Anahtar Kelimeler: Crizotinib, non-small cell lung cancer, prognosis, ROS1 fusion, MULTICENTER, NSCLC
  • İstanbul Üniversitesi Adresli: Evet

Özet

OBJECTIVEROS1 positivity is seen in 1-2% of patients with metastatic lung cancer. Targeted drugs such as crizotinib, lorlatinib, and entrectinib are used in the treatment. We aimed to evaluate the efficacy of crizotinib and the prognosis of patients with ROS1 fusion-positive metastatic non-small cell lung cancer (NSCLC) in this study. METHODSWe analyzed data of the advanced NSCLC patients with ROS1 mutation retrospectively. We determined the clinicopathological features of the patients. We evaluated the parameters affecting the prognosis with survival analyzes.RESULTSThe research enlisted the participation of 21 patients. Median progression-free survival with crizotinib treatment was found 26.1 (95% Confidence interval [CI], 8.1-44.1) months. Median overall survival was 35.2 (95% CI, 13.5-56.9) months. Treatment-related Grade 1-2 adverse effects were observed in 9 (42.9%) patients and Grade 3-4 adverse effects were detected in 1 (4.8%) patient. Clinicopathological parameters affecting survival were evaluated; age (p=0.02) and liver metastasis (p=0.03) were defined as prognostic parameters. ROS1 positivity rate (p=0.08) was not found to be a prognostic factor.CONCLUSIONIn patients with ROS1 fusion-positive metastatic NSCLC, crizotinib was shown to be both efficacious and safe. We also found that in this patient group, age and the existence of liver metastases are prognostic factors.